China SXT Pharmaceuticals, Inc.(SXTC)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
China SXT Pharmaceuticals, Inc. (SXTC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SXTC is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $7.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2026), China SXT Pharmaceuticals, Inc. reports quarterly revenue of $1.1M, net income of $-6.2M. Top institutional holders of SXTC by reported 13-F value include BANK OF MONTREAL, ACADIAN ASSET MANAGEMENT, PROEQUITIES, based on the most recent SEC filings. SXTC trades on the Nasdaq exchange and files with the SEC under CIK 1723980. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SXTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for China SXT Pharmaceuticals, Inc. directly from SEC EDGAR.
Revenue
$1.1M
Net Income
$-6.2M
SXTC key financials by period
China SXT Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2026
20-F
$1.1M
$-6.2M
—
FY 2025
20-F
$1.7M
$-3.3M
-154.0%
FY 2024
20-F
$1.9M
$-3.1M
-130.4%
FY 2023
20-F
$2.0M
$-5.9M
—
FY 2022
20-F/A
$2.6M
$-5.7M
-199.4%
FY 2021
20-F/A
$4.8M
$-2.7M
-46.0%
Institutions holding SXTC
Institutional investors reporting a position in China SXT Pharmaceuticals, Inc. on SEC Form 13F.
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $7.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
Price Chart
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
